Full-Time
Regenerative medicine, surgical devices provider
$71.3k - $97.8k/yr
Columbia, MD, USA
Hybrid
Three days on-site per week required.
Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Plainsboro Township, New Jersey
Founded
1989
Help us improve and share your feedback! Did you find this helpful?
People at Integra LifeSciences who can refer or advise you
Medical Insurance
Dental Insurance
Vision Insurance
Short-Term Disability
Long-Term Disability
401(k) Retirement Plan
Integra LifeSciences reported Q4 revenue of $435 million and adjusted earnings per share above guidance midpoint, but faces headwinds in 2025. Full-year revenue reached $1.635 billion with 0.7% organic decline, whilst gross margin fell 260 basis points to 61.9% due to tariffs, quality remediation and supply constraints. For 2026, the company guided revenue of $1.66 billion to $1.7 billion and adjusted EPS of $2.30 to $2.40, excluding potential new tariff impacts. Management expects operating cash flow exceeding $200 million and plans to reduce leverage from 4.5 times to 2.5–3.5 times by year-end. The company highlighted operational improvements including a new operating model, supply-chain resilience and early relaunches of PriMatrix and DuraRepair. A Braintree facility launching by June should support SurgiMend's Q4 2026 return.
Integra LifeSciences shares fell 3.5% after the medical device company issued weak revenue guidance for the first quarter and reported a significant drop in profitability. The company forecast first-quarter revenue of $382.5 million, 2.8% below analyst expectations. Whilst fourth-quarter revenue of $434.9 million and adjusted earnings per share of $0.83 beat expectations, underlying metrics showed deterioration. Revenue declined 1.7% year-over-year, operating margin fell sharply to 5.3% from 14.5% the previous year, and free cash flow was negative $5.4 million compared to positive $21.14 million a year ago. The combination of weak outlook and deteriorating profitability overshadowed the headline beats. Shares are down 6.9% year-to-date and trading 53.3% below their 52-week high.
Integra LifeSciences reported Q4 2025 revenue of $434.9 million, beating analyst estimates by 1% but declining 1.7% year on year. The medical device company's adjusted earnings per share of $0.83 exceeded expectations by 3.7%. However, the company's Q1 2026 revenue guidance of $382.5 million fell 2.8% below analyst estimates. Operating margin dropped to 5.3% from 14.5% in the prior year quarter, whilst free cash flow turned negative at -$5.4 million. Founded in 1989, Integra develops medical technologies for neurosurgery, wound care and surgical reconstruction. The company has struggled with tepid growth, recording just 3.6% compound annual revenue growth over five years. Its organic revenue rose 2.5% year on year in the quarter.
Medical device company Integra LifeSciences will report earnings tomorrow, with analysts expecting revenue to decline 2.7% year on year, reversing an 11.5% increase from the same quarter last year. The company missed revenue expectations last quarter, reporting $402.1 million in revenues, up 5.6% year on year. It also significantly missed revenue guidance for the following quarter. Integra has missed Wall Street's revenue estimates multiple times over the past two years. Analysts have generally reconfirmed their estimates over the last 30 days. Integra's shares are up 5.7% over the past month, outperforming the healthcare equipment segment's 1.9% decline. The stock currently trades at $11.70 against an average analyst price target of $15.50.
DECCO recognized for "Excellence in Construction" WOBURN, MA - The Massachusetts Chapter of Associated Builders and Contractors (ABC MA) congratulates DECCO for earning an Eagle Award at the 33rd annual Excellence in Construction Awards for their outstanding work on Integra Life Sciences' Project Revere. Nearly 250 ABC members gathered at the Four Points by Sheraton Hotel in Norwood on November 6th to recognize and celebrate the very best construction projects their companies have to offer. This year's applicant pool was particularly competitive, with each winner selected for the high standards of craftsmanship, safety and quality delivered by talented merit shop workers using the efficient merit shop approach. "We are proud to recognize the outstanding work of our member contractors through the ABC Excellence in Construction Awards," said ABC MA President Greg Beeman. "The winning contractors maintained a constant focus on meeting their clients' needs and set a high bar for craftsmanship, quality and safety." The Eagle Award DECCO won for Project Revere is the pinnacle of achievement. It recognizes overall excellence in project execution, craftsmanship, safety, innovative elements and challenges, and client satisfaction. The Massachusetts Chapter of Associated Builders and Contractors is the largest construction trade association in the Commonwealth, representing nearly 500 local general contractor, subcontractor, supplier and associate members that employ over 20,000 workers throughout Massachusetts.